An observational study in Myotonic Dystrophy 1, DM1 and Myotonic Dystrophy Type 1, sponsored by Fundació Institut Germans Trias i Pujol. Recruiting at 8 sites in Spain. Per ClinicalTrials.gov, last updated 2026-11-03.
Sponsored by Fundació Institut Germans Trias i Pujol · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Myotonic Dystrophy with a site in Spain — 9 open to participants now, 10 under way, 5 of them phase 3. Myotonic Dystrophy · Spain.
Among the 12 studies in Myotonic Dystrophy with a site in Spain, this one is one of 5 that started in 2025, is the only observational one, and was the 10th registered.
127 studies on the registry are indexed under Myotonic Dystrophy; 50 are open to participants now.
Browse Myotonic Dystrophy studies →9 of the 12 studies in Myotonic Dystrophy with a site in Spain are open now. Recruiting first, the newest first:
Avidity Biosciences, Inc. · Sites in Spain, Australia, Belgium and 7 more countries
Ages 7–16 · Men only
Dyne Therapeutics · Sites in Spain, United States, Australia and 9 more countries
Ages 16+
Lupin Ltd. · Sites in Spain, Belgium, Denmark and 3 more countries
Ages 16+
ARTHEx Biotech S.L. · Sites in Spain, United States, Canada and 4 more countries
Ages 18–64
Lupin Ltd. · Sites in Spain, Belgium, Denmark and 3 more countries
Ages 16+
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 35 Myotonic Dystrophy studies recruiting now, 15 (43%) set no upper age limit and 18 (51%) stop at 75 or younger; 22 take children under 18; 8 take healthy volunteers.
This study: all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 4 · Phase 3 6
First in 2020; this study’s year is marked. 5 started in 2025.
This study's planned enrollment of 3,000 is above the median of 100 across 56 observational studies indexed under Myotonic Dystrophy.
Median enrollment 78 across the 11 interventional studies, 3,000 across the 1 observational. Of the 2 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 12 have an industry lead sponsor. The 8 most frequent:
Fundació Institut Germans Trias i Pujol is the lead sponsor of 25 studies on the registry; 9 are open to participants now.
Fundació Institut Germans Trias i Pujol has 1 study filed under Myotonic Dystrophy — fewer than ten, so there is no comparison to draw.
5 of the studies in Myotonic Dystrophy with a site in Spain that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06523400Phase 3Lupin Ltd.The Efficacy and Safety of Once Daily Mexiletine PR in Patients With Myotonic Dystrophy Type 1 and Type 2 | 2027-06 |
| NCT06138743Sarepta Therapeutics, Inc.Study of SRP-1003 in Participants With Type 1 Myotonic Dystrophy | 2026-12-31 |
| NCT07385443Fundació Institut Germans Trias i PujolThe Spanish National Registry for Myotonic Dystrophy Type 1 | 2026-12-31 |
| NCT06185764Vertex Pharmaceuticals IncorporatedA Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1) | 2027-02-02 |
| NCT06300307ARTHEx Biotech S.L.Study of ATX-01 in Participants With DM1 | 2027-07 |
Add all 5 to your calendar (.ics) → With an account.
Among the 12 studies in Myotonic Dystrophy with a site in Spain, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Myotonic Dystrophy Type 1 (DM1) is a rare genetic neuromuscular condition that can affect multiple organs and varies widely in how it presents. DM1 is the most common form of adult-onset muscular dystrophy, with an estimated prevalence of approximately 1-5 per 10,000 people. In Spain, the condition shows notable regional differences, making it especially important to understand its characteristics within the population.
The aim of this study is to support a research initiative designed to better characterise DM1. We are developing a comprehensive national registry, collecting patient-reported information, clinical data and omics data that will improve our understanding of the disease and help identify individuals who may be eligible for clinical trials.
The DM1-Hub Patient Registry (https://www.dm1spain.com/) aims to recruit individuals living in Spain with a confirmed genetic diagnosis of myotonic dystrophy type 1 (DM1). Participants may be referred by healthcare professionals or patient organizations. They may also learn about the registry through outreach activities, informational materials, collaborations with national and local patient associations, DM1-Hub events, or through their own online searches.
After completing the informed consent process with their neurologist, participants are connected with the DM1-Hub patient support staff assigned to their hospital. An appointment is scheduled, and all the data collected is entered into the REDCap database.
The objective of this study is to establish a Natural History Patient Registry for individuals with DM1 in Spain. Participants will be invited to take part in follow-up assessments to support the characterization of disease progression over time. A parallel control group will also be recruited to facilitate biomarker discovery and improve understanding of factors associated with disease prognosis.
Participants with Myotonic Dystrophy Type 1 (DM1) will volunteer to participate in this study. The study will be advertised through physician recommendations, outreach and educational activities directed at neuromuscular professionals, the registry website, national and local patient associations, and through patient-focused events, conferences, and scientific meetings across Spain.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The group included Individuals with a confirmed genetic diagnosis of Myotonic Dystrophy Type 1 (DM1)
Other: Patient Registry
The group included control subjects as individuals without a genetic diagnosis of Myotonic Dystrophy Type 1 (DM1).
Other: Patient Registry
Patient Registry
Genomic Caracterization
Long-read genomic sequencing analyses encompassing CTG expansion characterization and whole-genome genetic and epigenetic profiling.
Time frame: 1 year, year 1
Proteomic Characterization
Biomarker evaluation
Time frame: 1 year, year 1
WAIS IV neuropsychological tests
IQ, memory, attention, language
Time frame: 2 years, year 1
vHOT
Video Hand Opening Time, clinical measure for Myotonic Dystrophy (DM1) tracking hand reopening speed
Time frame: 1 year, year 1
Muscular Impairment Rating Scale (MIRS)
The Muscular Impairment Rating Scale is a 5-point ordinal clinical scale used to evaluate the severity of muscular impairment in patients with myotonic dystrophy. Scores range from 1 (minimal or no impairment) to 5 (severe muscle impairment). Higher scores indicate worse functional impairment.
Time frame: 1 year, year 1
Hand Grip Strength
Hand grip strength is assessed as a measure of upper limb muscle strength using a hand-held dynamometer. Grip strength is measured separately in the dominant and non-dominant hand, and recorded in kilograms (kg). For each hand, three consecutive attempts are performed, alternating between hands to minimize fatigue. The maximum value (best of three attempts) for each hand is recorded and used for analysis. Higher values indicate better muscle strength and functional outcome, while lower values reflect greater muscular impairment.
Time frame: 1 year, year 1
6MWT
Six-Minute Walk Test
Time frame: 1 year, year 1
10MWRT
10-meter Walk/Run Test
Time frame: 1 year, year 1
30CST
30-Second Chair Stand Test
Time frame: 1 year, year 1
FVC
Forced Vital Capacity (L)
Time frame: 1 year, year 1
Electrocardiogram (ECG)
The following ECG-derived parameters and abnormalities are recorded: * PR interval duration (milliseconds) * QRS complex duration (milliseconds) * Presence of atrioventricular block (AV block) (yes/no), and AV block grade when present (first degree, second degree Mobitz I, second degree Mobitz II, third degree) * Presence of supraventricular arrhythmias (yes/no) * Presence of ventricular arrhythmias (yes/no) * Other electrocardiographic abnormalities, recorded as free text when applicable All measurements are extracted from the ECG tracing according to standard clinical practice. Higher PR or QRS durations and the presence of conduction abnormalities or arrhythmias indicate greater cardiac involvement, while normal values and absence of abnormalities indicate preserved cardiac electrical function.
Time frame: 1 year, year 1
BMI
Body Mass Index
Time frame: 1 year, year 1
OBGYN events
Collection of gynecological clinical history and relevant reproductive health events for participants who opt to provide this information.
Time frame: 1 year, year 1
GI symptomatology
Collection of participant-reported gastrointestinal symptoms and related clinical information.
Time frame: 1 year, year 1
MBS (Myotonia Behaviour Scale)
Myotonia severity is assessed using the Myotonia Behaviour Scale (MBS), a clinician-reported ordinal scale that evaluates the functional impact of myotonia-related muscle stiffness on daily activities. The scale ranges from 0 to 5, with higher scores indicating greater severity and functional interference due to myotonia: 0: No muscle stiffness 1. Mild stiffness present but easily ignored 2. Stiffness present and occasionally noticeable but does not interfere with daily activities 3. Stiffness requiring increased concentration to perform certain tasks or activities 4. Stiffness interfering with all tasks and daily activities 5. Severe, disabling stiffness requiring constant movement to avoid complete motor blockage Lower scores reflect minimal or absent myotonia, while higher scores reflect greater functional impairment due to myotonia.
Time frame: 1 year, year 1
Modified Rankin Scale (mRS)
Global disability is assessed using the Modified Rankin Scale (mRS), a widely used ordinal scale measuring the degree of disability or dependence in daily activities. The scale ranges from 0 to 6, with higher scores indicating greater disability or death: 0: No symptoms 1. No significant disability; able to carry out all usual activities despite symptoms 2. Slight disability; unable to perform all previous activities but able to manage own affairs without assistance 3. Moderate disability; requiring some help but able to walk without assistance 4. Moderately severe disability; unable to walk without assistance and unable to attend to bodily needs without help 5. Severe disability; bedridden, incontinent, and requiring constant nursing care and attention 6. Death
Time frame: 1 year, year 1
Patient-Reported Outcome: Quality of life
INQoL (Individualized Neuromuscular Quality of Life Questionnaire)
Time frame: 1 year, year 1
Patient-Reported Outcome: Fatigue
FSS (Fatigue Severity Scale )
Time frame: 1 year, year 1
Patient-Reported Outcome: Dietary Habits
MEDAS-14 (Mediterranean Diet Adherence Screener)
Time frame: 1 year, year 1
Patient-Reported Outcome: Sleepiness
DSS (Daytime Sleepiness Scale)
Time frame: 1 year, year 1
Patient-Reported Outcome: Apathy
AES (Apathy Evaluation Scale)
Time frame: 1 year, year 1
Patient-Reported Outcome: Physical Activity
IPAQ (International Physical Activity Questionnaire)
Time frame: 1 year, year 1
Patient-Reported Outcome: Mental Health
MHI-5 (Mental Health Inventory)
Time frame: 1 year, year 1
Plan to share: Undecided
Started Jun 2025 (actual). Primary completion is estimated for Dec 2026, 18 months after the start.
Of 36 observational studies under Myotonic Dystrophy, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 35. This study's planned 18 months is below that.
Completion moved once since we started tracking on Sep 25, 2026: Dec 2026 → Dec 2035, on Nov 3, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fundació Institut Germans Trias i Pujol